Please ensure Javascript is enabled for purposes of website accessibility

3 Top Dividend Stocks to Buy Now

By Todd Campbell – Updated Jan 4, 2018 at 3:40PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

If you're trying to narrow down a list of dividend stocks that can still be bought with markets near all-time highs, you ought to consider Microsoft, UnitedHealth Group, and Johnson & Johnson.

This article was updated on Dec. 16, 2017, and originally published on Feb. 28, 2017. 

Despite the stock market's big run-up, shares in Microsoft (MSFT -1.94%), UnitedHealth Group (UNH -0.74%), and Johnson & Johnson (JNJ -0.71%) could still be heading higher. If so, investors savvy enough to have added these three top dividend stocks to their income portfolios could make out handsomely, because all three companies have an opportunity to overdeliver on cash flow and profit.

A technology titan turning the corner 

It wasn't too many years ago that investors were shunning Microsoft shares, fearful that a dying PC market would be the end to this company's long winning streak. However, a portfolio of cloud software products that are perfectly suited to today's decentralized workplace has caught fire with companies of all sizes, and that's rekindled interest in this technology powerhouse.

A business man with an oversized magnet attracting money to him


To be clear, the company's still got more work to do. The PC business is still tough, but next-generation solutions are growing quickly, and because of their high margins, they're providing profit-friendly tailwinds. In its fiscal first quarter of 2018, the company's personal computing business declined 1% from a year ago, but productivity and business processes revenue grew 28% to $8.2 billion, and intelligent cloud segment sales grew 13% to $6.9 billion.

Productivity and business processes growth was driven by 42% increase in Office 365 commercial revenue, while intelligent cloud sales were driven by 89% growth for Azure, Microsoft's app development and management business.

Overall, growth in Microsoft's higher-margin businesses helped the company deliver net income of $6.6 billion, up 16% from last year, and diluted earnings per share of $0.84, up 17% from a year ago. That profit growth bodes well for dividend investors because it means there's more money available for dividend hikes. Currently, investors are getting $0.42 per share in quarterly dividends, up from $0.39 per share in quarterly dividends last year. As a result,  Microsoft's shares still yield a competitive 1.9%, despite a run-up in its share price.

Big changes could create big opportunity

A huge amount of uncertainty exists in the health insurance industry right now. Donald Trump's winning the White House in 2016 means that a repeal and replacement of Obamacare is still possible, and while it's not clear yet what a replacement will be, big insurers like UnitedHealth Group, the nation's largest insurer, could be rewarded.

After losing hundreds of millions of dollars selling Obamacare plans, UnitedHealth Group became one of Obamacare's biggest critics. The company decided to exit most of the Affordable Care Act's exchanges in 2016, and in 2017, it only offered plans in a handful of states, down from more than 30 states in 2016.

Since UnitedHealth Group's already exited the majority of the ACA state exchanges, a repeal is likely to be far less disruptive to it than it is to competitors. The company's vast experience in managing health insurance plans, however, means it's still one of the best-positioned companies to profit from any Obamacare replacement. 

Despite losing money on Obamacare in 2016, UnitedHealth Group remains one of America's most financially healthy insurers. Strength in its Medicaid, Medicare, and employer health insurance businesses more than offset Obamacare headwinds in 2016, and as a result, full-year operating profit jumped 20% to $13 billion and adjusted earnings per share grew 25% to $8.05 in 2016. 

Business has similarly been good in 2017. For instance, third-quarter sales climbed to $50.3 billion from $46.3 billion a year ago, and net margin grew to 4.9% from 4.3%. As a result, adjusted net earnings grew 23% to $2.66 per share from $2.17 per share in the third quarter of 2016.

Assuming Congress does end up replacing Obamacare at some point with a more profitable alternative, the potential for UnitedHealth Group to grow its bottom line in the coming years is significant. But even if an Obamacare replacement is a dud, UnitedHealth has shown it can still deliver plenty of dividend-friendly bottom-line growth. Job growth is boosting enrollment in its workplace insurance plans and aging baby boomers offer tremendous growth for its Medicare Advantage plans. 

A set-it-and-forget-it stock

Perhaps no company is more deeply tied to global healthcare markets than Johnson & Johnson. Its over-the-counter brands are some of the planet's most widely recognized, and its pharmaceuticals and medical devices are among the most popular choices among doctors worldwide.

Consumer brands like Band-Aid keep cash flowing, offsetting some risk to investors, while a prolific drug research and development program fuels Johnson & Johnson's growth. For example, it's fastest-growing drugs are the multiple myeloma drug Darzalex and the leukemia drug Imbruvica. Darzalex sales soared to $871 million in the first nine months of 2017 from $372 million in the first nine months of 2016. Meanwhile, Imbruvica's sales jumped 52% year-over-year to $1.4 billion in the first nine months of 2017. These two drugs are emblematic of Johnson & Johnson's success at commercializing next-generation medicine.

Granted, the drug industry is a hypercompetitive and expiring patents means more competition is coming, but management has decades of experience navigating patent risk, and with some of the deepest pockets in the industry, I'm confident Johnson & Johnson will innovate new drugs that help it sidestep its competitors. 

Overall, if you want to own fast-growing dividend stocks in your income portfolio, then there could be better options, but if your goal is to own a steady-Eddy performer with an enviable track record of dividend increases, then it's hard to argue against buying Johnson & Johnson's stock. 


Teresa Kersten is an employee of LinkedIn and is a member of The Motley Fool’s board of directors. LinkedIn is owned by Microsoft. Todd Campbell owns shares of Microsoft. The Motley Fool owns shares of and recommends Johnson & Johnson. The Motley Fool recommends UnitedHealth Group. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Johnson & Johnson Stock Quote
Johnson & Johnson
$163.36 (-0.71%) $-1.17
Microsoft Corporation Stock Quote
Microsoft Corporation
$232.90 (-1.94%) $-4.60
UnitedHealth Group Incorporated Stock Quote
UnitedHealth Group Incorporated
$505.04 (-0.74%) $-3.79

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/03/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.